Priority Date: 24.03.11 (EP 20110305330)

DOMINANT NEGATIVE HSP110 MUTANT AND ITS USE IN PROGNOSING AND TREATING CANCERS

  • Application ID: EP12710730
  • Status: NO OPPOSITION FILED WITHIN TIMELIMIT

Attorneys

operating since 1999
Headquarter in Paris
active in Legal Services and IP Consulting
no operation time available
1093.85
2 offices
active in Legal Services

Specialization

This EP application has the IPC class C07, C12, and G01. We found, that TransMIT GmbH, Kailuweit & Uhlemann, dompatent von Kreisler Selting Werner - Partnerschaft von Patent- und Rechtsanwälten mbB, Kilburn & Strode LLP, Potter Clarkson LLP and 62 others are specialized in this combination either. For a similar patent, they might be a good choice.

Timeline

  • 24.03.2011 - Priority Date (EP 20110305330)
  • 27.09.2012 - Publication A1 (WO2012127062)
  • 29.01.2014 - Publication A1 (EP2688907)
  • 27.04.2016 - Publication B1 (EP2688907)